Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2010 - 2026)

Neuroone Medical Technologies (NMTC) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 42.82% year-over-year to $6.2 million; the trailing twelve-month figure through Jun 2026 stood at $33.1 million (up 22.02% YoY), and the FY2025 full-year result was $10.8 million, up 100.85% from the prior year.
• Liabilities and Shareholders Equity declined to $6.2 million in Q2 2026 per NMTC's latest filing, from $7.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.1 million in Q1 2022 and bottomed at $4.5 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $8.1 million across 5 years, with a median of $7.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 50.24% in 2023, then jumped 120.24% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $9.7 million in 2022, then sank by 39.73% to $5.8 million in 2023, then advanced by 11.54% to $6.5 million in 2024, then jumped by 32.08% to $8.6 million in 2025, then slipped by 27.88% to $6.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.2 million, $7.6 million, and $8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.